



SmartPA Criteria Proposal

Drug/Drug Class:	Psychotropic Medications Polypharmacy Clinical Edit
First Implementation Date:	November 5, 2010
Revised Date:	February 23, 2023
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate and prudent use psychotropic medications

Why Issue Selected: MO HealthNet will assess the usage of psychotropic agents in the pharmacy program with a primary goal of patient safety in regard to polypharmacy or use of more drugs than is medically necessary. Participants may have multiple prescribers and/or multiple pharmacies caring for them, and, by using medical evidence guidelines, this clinical edit can flag potentially dangerous duplication within drug classes, dangerous drug interactions, or overmedication. The edit helps to provide an “early warning alert” to the pharmacist filling the prescription and the prescribing physician. As always, if a provider wishes to override a denial for medically necessary reasons, a claim can be approved with further medical input through direct communication with the MHD Hotline.

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Psychotropic medications
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Demonstrated compliance to prescribed therapy (90 out of 120 days) for participants ≥ 18 years of age who are not enrolled in foster care **OR**
- Participant ≤ 5 years of age: history of ≤ 3 different psychotropic medications in the past 60 days **OR**
- Participant ≥ 6 years of age: history of ≤ 5 different psychotropic medications in the past 60 days
- Documented diagnosis of a seizure disorder: all seizure medications are not counted in a participant’s past history of psychotropic medications

Denial Criteria

- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

X

Disposition of Edit

Denial: Exception code **“1010” (Therapeutic Duplication)**
Rule Type: CE

Default Approval Period

3 months

Appendix A – Agents in the Psychotropic Medications Polypharmacy Clinical Edit

Psychotropic Medications
ALPRAZOLAM
AMITRIPTYLINE HCL
AMITRIPTYLINE/CHLORDIAZEPOXIDE
AMOBARBITAL SODIUM
AMOXAPINE
AMPHETAMINE
AMPHETAMINE SULFATE
ARIPIPRAZOLE
ARIPIPRAZOLE LAUROXIL
ARIPIPRAZOLE LAUROXIL, SUBMICRONIZED
ARMODAFINIL
ASENAPINE
ASENAPINE MALEATE
ATOMOXETINE HCL
BREMELANOTIDE ACETATE
BREXPIRAZOLE
BRIVARACETAM
BUPROPION HBR
BUPROPION HCL
BUSPIRONE HCL
CANNABIDIOL (CBD)
CARBAMAZEPINE
CARIPRAZINE HCL
CENOAMATE
CHLORDIAZEPOXIDE HCL
CHLORDIAZEPOXIDE/CLIDINIUM BR

SmartPA Clinical Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

Psychotropic Medications continued
CHLORPROMAZINE HCL
CITALOPRAM HYDROBROMIDE
CLOBAZAM
CLOMIPRAMINE HCL
CLONAZEPAM
CLONIDINE HCL
CLORAZEPATE DIPOTASSIUM
CLOZAPINE
DARIDOREXANT HCL
DESIPRAMINE HCL
DESVENLAFAXINE
DESVENLAFAXINE SUCCINATE
DEUTETRABENAZINE
DEXMEDETOMIDINE HCL
DEXMETHYLPHENIDATE HCL
DEXTROAMPHETAMINE
DEXTROAMPHETAMINE SULFATE
DEXTROAMPHETAMINE/AMPHETAMINE
DEXTROMETHORPHAN HBR/BUPROPION HCL
DEXTROMETHORPHAN HBR/QUINIDINE SULFATE
DIAZEPAM
DIVALPROEX SODIUM
DOXEPIN HCL
DROPERIDOL
DULOXETINE HCL
ESCITALOPRAM OXALATE
ESKETAMINE HCL
ESLICARBAZEPINE ACETATE
ESTAZOLAM
ESZOPICLONE
ETHOSUXIMIDE
ETHOTOIN
FELBAMATE
FENFLURAMINE HCL
FLIBANSERIN
FLUOXETINE HCL
FLUPHENAZINE DECANOATE
FLUPHENAZINE HCL
FLURAZEPAM HCL
FLUVOXAMINE MALEATE
FOSPHENYTOIN SODIUM
GABAPENTIN
GABAPENTIN ENACARBIL
GABAPENTIN/LIDOCAINE
GABAPENTIN/LIDOCAINE HCL/GAUZE BANDAGE/S
GABAPENTIN/LIDOCAINE HCL/MENTHOL
GABAPENTIN/LIDOCAINE HCL/SILICONE ADHESI

SmartPA Clinical Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

Psychotropic Medications continued
GABAPENTIN/LIDOCAINE/PRILOCAINE/TRANSPAR
GANAXOLONE
GUANFACINE HCL
HALOPERIDOL
HALOPERIDOL DECANOATE
HALOPERIDOL LACTATE
ILOPERIDONE
IMIPRAMINE HCL
IMIPRAMINE PAMOATE
ISOCARBOXAZID
LACOSAMIDE
LAMOTRIGINE
LEMBOREXANT
LEVETIRACETAM
LEVETIRACETAM IN NACL (ISO-OS)
LEVOMILNACIPRAN HCL
LISDEXAMFETAMINE DIMESYLATE
LITHIUM CARBONATE
LITHIUM CITRATE
LORAZEPAM
LOXAPINE
LOXAPINE SUCCINATE
LUMATEPERONE TOSYLATE
LURASIDONE HCL
MAPROTILINE HCL
MEPROBAMATE
METHAMPHETAMINE HCL
METHSUXIMIDE
METHYLPHENIDATE
METHYLPHENIDATE HCL
MIDAZOLAM
MIDAZOLAM HCL
MIDAZOLAM/KETAMINE HCL/ONDANSETRON HCL
MILNACIPRAN HCL
MIRTAZAPINE
MODAFINIL
MOLINDONE HCL
NEFAZODONE HCL
NORTRIPTYLINE HCL
OLANZAPINE
OLANZAPINE PAMOATE
OLANZAPINE/FLUOXETINE HCL
OLANZAPINE/SAMIDORPHAN MALATE
OXAZEPAM
OXCARBAZEPINE
PALIPERIDONE
PALIPERIDONE PALMITATE

SmartPA Clinical Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

Psychotropic Medications continued
PAROXETINE HCL
PAROXETINE MESYLATE
PENTOBARBITAL SODIUM
PERAMPANEL
PERPHENAZINE
PERPHENAZINE/AMITRIPTYLINE HCL
PHENELZINE SULFATE
PHENOBARBITAL
PHENOBARBITAL SODIUM
PHENYTOIN
PHENYTOIN SODIUM
PHENYTOIN SODIUM EXTENDED
PIMAVANSERIN TARTRATE
PIMOZIDE
PITOLISANT HCL
PREGABALIN
PRIMIDONE
PROTRIPTYLINE HCL
QUAZEPAM
QUETIAPINE FUMARATE
RAMELTEON
RISPERIDONE
RISPERIDONE MICROSPHERES
RUFINAMIDE
SECOBARBITAL SODIUM
SELEGILINE
SERDEXMETHYLPHEN/DEXMETHYLPHEN
SERTRALINE HCL
SODIUM OXYBATE
SODIUM OXYBATE/CALCIUM OXYBATE/MAGNESIUM
SOLRIAMFETOL HCL
STIRIPENTOL
SUVOREXANT
TASIMELTEON
TEMAZEPAM
TETRABENAZINE
THIORIDAZINE HCL
THIOTHIXENE
TIAGABINE HCL
TOPIRAMATE
TRANLYCYPROMINE SULFATE
TRAZODONE HCL
TRIAZOLAM
TRIFLUOPERAZINE HCL
TRIMIPRAMINE MALEATE
VALBENAZINE TOSYLATE

SmartPA Clinical Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

Psychotropic Medications continued
VALPROIC ACID
VALPROIC ACID (AS SODIUM SALT)
VENLAFAXINE BESYLATE
VENLAFAXINE HCL
VIGABATRIN
VILAZODONE HCL
VILOXAZINE HCL
VORTIOXETINE HYDROBROMIDE
ZALEPLON
ZIPRASIDONE HCL
ZIPRASIDONE MESYLATE
ZOLPIDEM TARTRATE
ZONISAMIDE

SmartPA Clinical Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.